BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 6.38%.
BioCryst Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.09 in the quarter versus EPS of $-0.13 in the year-earlier quarter.
Revenue: Decreased 70.95% to $3.55 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: BioCryst Pharmaceuticals, Inc. reported adjusted EPS loss of $0.09 per share. By that measure, the company beat the mean analyst estimate of $-0.15. It beat the average revenue estimate of $1.31 million.
Quoting Management: “We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst. “In addition, our Phase 1 clinical trial of BCX4161 in healthy subjects is progressing. We expect to complete this clinical trial and report results this summer. If this trial is successful, we plan to initiate a Phase 2 program in hereditary angioedema patients this year.”
Key Stats (on next page)…
Revenue decreased 13.41% from $4.1 million in the previous quarter. EPS increased to $-0.09 in the quarter versus EPS of $-0.18 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.08 to a loss $0.13. For the current year, the average estimate has moved down from a loss of $0.36 to a loss of $0.50 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)